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In a previous study, we have identi	ed 3-alkyl-1,5-diaryl-1H-1,2,4-triazoles to be a novel class of cannabinoid type 1 receptor (CB1R)
antagonists. In order to expand the number of cannabinoid ligands with a central 1,2,4-triazole scaold, we have synthesized a novel
series of 1-benzyl-1H-1,2,4-triazoles, and some of themwere evaluated by CB1R radioligand binding assays. Compound 12a showed
the most interesting pharmacological properties, possessing a CB1R anity in the nanomolar range.
1. Introduction
Due to the potential therapeutic eects of cannabinoids
that include antiemetic, analgesic, antiglaucoma, obesity
treatment, alcoholism, bronchodilatation, and inammation,
a considerable number of cannabinoid ligands have been
reported in recent years [1]. eir eects are mediated
through G-protein coupled cannabinoid receptors, which
are part of the endocannabinoid system (ECS) [2]. So far,
two types of cannabinoid receptors, designated as CB1R
and CB2R, have been well characterized, and three puta-
tive cannabinoid receptors, GPR55, GPR18, and GPR119,
have been also proposed [3]. CB1R has been found in
the peripheral and central nervous system, and CB2R is
mainly present in the immune system. Cannabinoid ligands
belong to families of diverse structural classes such as
eicosanoids, classical and nonclassical ligands related to Δ9-
tetrahydrocannabinol (THC), and heterocycles. Among the
heterocycles family, pyrazoles [4] and aminoalkylindoles [5]
are the most representative ligands.
In our early research program, it was found that
triazole motif was an attractive scaold for cannabi-
noid activity [6]. We reported that the CB1R antago-
nist 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-3-hexyl-1H-
1,2,4-triazole (LH21) exhibited antiobesity activity in in vivo
assays (Figure 1) [7–9]. Pyrazole [10] and pyrrole [11] cannabi-
noid ligands bearing a benzyl substituent on positionN1 have
been reported in the literature as CB2R antagonists (Figure 1).
is prompted us to extend our previous investigation by syn-
thesizing a series of 3-alkyl-5-aryl-1-benzyl-1H-1,2,4-triazoles
in order to establish structure-activity relationships.
We describe herein the synthesis of new benzyl-1,2,4-
triazoles [12] and present initial results from radioligand
binding assays as part of our investigation on cannabinoid
active compounds.
2. Materials and Methods
2.1. Chemistry
2.1.1. General. All reagents and solvents were used as com-
mercially received. EtOH was dried over magnesium. TLC
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Figure 1: Structure of the CB1R antagonist LH21 and the CB2R antagonists SR144528 andN-(1S,2R)-myrtanyl-5-(4-chloro-3-methylphenyl)-
1-(-4-methylbenzyl)-1H-pyrrole-3-carboxamide.
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Scheme 1
was carried out by precoated silica-gel 60 F254 plates (Merck)
and detection by UV light (254 nm). Flash-column chro-
matography was carried out by Kieselgel 60 (230–400mesh;
Merck). Medium pressure chromatography (MPLC) was
carried out by Flash Master Personal system with prepacked
silica-gel cartridges. e purity of the 	nal compounds
was determined by elemental analysis or analytical HPLC.
Elemental analysis was performed on a Heraeus CHN-O
rapid analyzer. Analyses indicated by the symbols of the
elements or functions were within ±0.4% of the theoretical
values, except compound 6. Analytical HPLC was run on a
Waters 6000 with Delta Pak C 18.5mm, 300> (3.9 × 150mm)
column, using an eluent Acetonitrile/H2O (0.05% H3PO4 +
0.04% TEA) in the proportion indicated in each case; ow
rate used was 1mL/min and the UV absorption was detected
at a wavelength of 254 nm. HPLC analyses were within≥90% of purity, except compound 11b (81% purity).emass
spectra (electrospray positive mode) were determined on a
MSD-Series 1100Hewlett Packard instrument.Melting points
(uncorrected) were determined with a Reichert Jung er-
movar apparatus. 1H and 13CNMR spectra were recorded on
a Gemini 200, Varian 300 and 400 unity spectrometers using
TMS as the internal standard. All chemical shis are reported
in ppm. For the assignment of the protons and carbons of the
aromatic rings Scheme 1 is used.
2.1.2. General Procedure for the Synthesis of 1 and 2. To a
suspension of the corresponding nitrile (10 equiv) in dry
EtOH (30–75mL) NaOMe (1 equiv) was added. It was stirred
at room temperature under N2 atmosphere for 48 h. Aer-
wards, ammonium chloride (10 equiv) was added, and the
stirring was maintained for 24 more hours. en, unreacted
ammonium chloride was 	ltered o and the solvent was
evaporated from the liquid layer.ewhite solid obtainedwas
washed with Et2O, dried, and used in the next step without
further puri	cation.
4-Chlorobenzimidamide Hydrochloride (1). Compound 1 was
prepared from 4-chlorobenzonitrile (10.00 g, 72.7mmol),
NaOMe (393mg, 7.3mmol), and ammoniumchloride (3.90 g,
72.7mmol). Yield: 4.34 g of 1 (31%) as awhite solid.Mp= 246-
247∘C (236–240∘C (EtOH)). [13] 1H-NMR (CD3OD) 훿: 8.02
(d, 2H, 퐽 = 9.0Hz, Ho); 7.84 (d, 2H, 퐽 = 9.0Hz, Hm). 13C-
NMR (CD3OD) 훿: 167.6 C=NH; 141.4 Cp; 130.8 and 130.7 Co
and Cm; 128.2 Cipso. MS (ES+)m/z: 155 (100%) [M+H]+.
4-Amidinopyridinium Hydrochloride (2). Compound 2 was
prepared from 4-cyanopyridine (2.50 g, 24.0mmol), NaOMe
(130mg, 2.4mmol), and ammonium chloride (1.28 g,
24.0mmol). Yield: 3.30 g of 2 (87%) as a white solid. Mp =
248-249∘C. 1H-NMR (CD3OD) 훿: 8.93 (d, 2H, 퐽 = 6.2Hz,
Hm); 7.87 (d, 2H, 퐽 = 6.2Hz, Ho). 13C-NMR (CD3OD) 훿:
166.9 C=NH; 151.7 Cm; 138.1 Cipso; 123.2 Co. MS (ES+) m/z:
122 (100%) [M+H]+.
2.1.3. General Procedure for the Synthesis of 3–5. To a solution
of the corresponding amidinium salt (1.5 equiv) in dry EtOH
(10–45mL), NaOMe (1 equiv) in 10mL of dry EtOH was
added. e suspension was stirred at room temperature for
1 h. en, the solid formed was 	ltered on Celite. Octanoic
hydrazide (2 equiv) was added to the liquid layer and the
mixture was stirred under reux for 46–49 h. Aer cooling
the reaction mixture, solvent was removed in vacuo. e
residue was dissolved in CH2Cl2 and washed with water (3 ×
20mL). e organic layer was dried over anhydrous Na2SO4
and the solvent was removed in vacuo. e obtained residue
was puri	ed by MPLC using cyclohexane/EtOAc (3 : 1) as
eluent, except for compound 5 where cyclohexane/EtOAc
(3 : 1 to 4 : 1) was used.
3-Heptyl-5-phenyl-1H-1,2,4-triazole (3). Compound 3 was
prepared from benzamidine hydrochloride hydrate (857mg,
5.5mmol), octanoic hydrazide (581mg, 3.6mmol), and
NaOMe (394mg, 7.3mmol). Yield: 683mg of 3 (78%) as a
transparent oil. Mp = 129–132∘C oxalate (to a solution of
the free base in Et2O, a solution of oxalic acid in EtOAc
was added; the white solid was 	ltered o, washed with
EtOAc, and dried). 1H-NMR (CDCl3) 훿: 10.65 (bs, 1H,
NH); 7.96 (m, 2H, Ho); 7.34 (m, 3H, Hm and Hp); 2.69
(t, 2H, 퐽 = 7.7Hz, CH2CH2CH2CH2CH2CH2CH3); 1.65
International Journal of Medicinal Chemistry 3
(p, 2H, 퐽 = 7.7Hz, CH2CH2CH2CH2CH2CH2CH3); 1.16
(m, 8H, CH2CH2CH2CH2CH2CH2CH3); 0.79 (bt, 3H,퐽 = 6.3Hz, CH3). 13C-NMR (CDCl3) 훿: 160.4 and 160.0
C3 and C5; 129.8 Cipso; 129.5 Cp; 128.6 Cm; 126.4 Co;
31.5 CH2CH2CH2CH2CH2CH2CH3; 29.1 CH2CH2CH2
CH2CH2CH2CH3; 28.8 CH2CH2CH2CH2CH2CH2CH3;
28.1 CH2CH2CH2CH2CH2CH2CH3; 27.0 CH2CH2CH2
CH2CH2CH2CH3; 22.5 CH2CH2CH2CH2CH2CH2CH3;
13.9 CH3. MS (ES+) m/z: 244 (100%) [M+H]+. Anal
(C15H21N3⋅C2H2O4) % calculated (% found) C: 61.25 (61.41);
H: 6.95 (7.12); N: 12.60 (12.62).
5-(4-Chlorophenyl)-3-heptyl-1H-1,2,4-triazole (4). Com-
pound 4 was prepared from 1 (1.00 g, 5.2mmol), octanoic
hydrazide (549mg, 3.5mmol), and NaOMe (375mg,
7.0mmol). Yield 392mg of 4 (40%) as a white solid. Mp =
108–111∘C. 1H-NMR (CDCl3) 훿: 7.91 (d, 2H, 퐽 = 8.6Hz, Ho);
7.34 (d, 2H, 퐽 = 8.6Hz, Hm); 2.72 (t, 2H, 퐽 = 7.6Hz, CH2CH2
CH2CH2CH2CH2CH3); 1.68 (p, 2H, 퐽 = 7.6Hz, CH2CH2
CH2CH2CH2CH2CH3); 1.20 (m, 8H, CH2CH2CH2CH2
CH2CH2CH3); 0.82 (bt, 3H, 퐽 = 6.5Hz, CH3). 13C-NMR
(CDCl3) 훿: 160.4 and 159.5 C3 and C5; 135.5 Cipso; 128.9
Cm; 128.7 Cp; 127.7 Co; 31.6 CH2CH2CH2CH2CH2CH2CH3;
29.2 CH2CH2CH2CH2CH2CH2CH3; 28.8 CH2CH2CH2
CH2CH2CH2CH3; 28.0 CH2CH2CH2CH2CH2CH2CH3;
26.9CH2CH2CH2CH2CH2CH2CH3; 22.5 CH2CH2CH2CH2
CH2CH2CH3; 14.0 CH3. MS (ES+)m/z: 278 (100%) [M+H]+.
Anal (C15H20ClN3) % calculated (% found) C: 64.85 (65.09);
H: 7.26 (7.42); N: 15.13 (15.35).
4-(3-Heptyl-1H-1,2,4-triazol-5-yl)pyridine (5) and N耠-[imi-
no(pyridin-4-yl)methyl]octa-nehydrazide (6). Compound 5
was prepared from 2 (2.00 g, 12.7mmol), octanoic hydrazide
(1.35 g, 8.5mmol), and NaOMe (918mg, 17.0mmol). Yield:
459mg of 5 (23%) as a white solid and 1.61 g of 6 (45%) as a
white solid. 5: Mp = 109–112∘C. 1H-NMR (CDCl3) 훿: 8.69 (d,
2H, 퐽 = 6.1Hz, Hm); 8.06 (d, 2H, 퐽 = 6.1Hz, Ho); 2.85 (t,
2H, 퐽 = 7.7Hz, CH2CH2CH2CH2CH2CH2CH3); 1.78 (p, 2H,퐽 = 7.7Hz, CH2CH2CH2CH2CH2CH2CH3); 1.21 (m, 8H,
CH2CH2CH2CH2CH2CH2CH3); 0.81 (bt, 3H, 퐽 = 6.7Hz,
CH3). 13C-NMR (CDCl3) 훿: 159.4 and 159.2 C3 and C5; 149.4
Cm; 139.5 Cipso; 121.0 Co; 31.5 CH2CH2CH2CH2CH2CH2
CH3; 29.1 CH2CH2CH2CH2CH2CH2CH3; 28.8 CH2CH2
CH2CH2CH2CH2CH3; 28.1 CH2CH2CH2CH2CH2CH2
CH3; 26.7 CH2CH2CH2CH2CH2CH2CH3; 22.5 CH2CH2
CH2CH2CH2CH2CH3; 13.9 CH3. MS (ES+) m/z: 245 (100%)
[M+H]+. Anal (C14H20N4) % calculated (% found) C: 68.82
(68.71); H: 8.25 (8.36); N: 22.93 (22.78). 6: Mp = 135–138∘C.1H-NMR (CD3OD) 훿: 8.67 (d, 2H, 퐽 = 6.1Hz, Hm); 7.94
(d, 2H, 퐽 = 6.1Hz, Ho); 2.41 (t, 2H, 퐽 = 7.4Hz, CH2CH2
CH2CH2CH2CH2CH3); 1.76 (m, 2H, CH2CH2CH2CH2
CH2CH2CH3); 1.41 (m, 8H, CH2CH2CH2CH2CH2CH2
CH3); 0,99 (bt, 3H, 퐽 = 6.0Hz, CH3). 13C-NMR (CD3
OD) 훿: 172.7 CONH; 151.7 C=NH; 150.4 Cm; 144.1
Cipso; 122.9 Co; 35.7 CH2CH2CH2CH2CH2CH2CH3; 32.9
CH2CH2CH2CH2CH2CH2CH3; 30.4 and 30.2 CH2CH2CH2
CH2CH2CH2CH3; 27.1 CH2CH2CH2CH2CH2CH2CH3; 23.7
CH2CH2CH2CH2CH2CH2CH3; 14.4 CH3. MS (ES+) m/z:
263 (100%) [M+H]+. Anal (C14H22N4O⋅1/2HCl) % calculated
(% found) C: 59.93 (59.10); H: 8.08 (8.11); N: 19.97 (20.45).
Intermediate 6 (1.00 g, 3.6mmol) in dry EtOH (20mL)
reacted by reuxing with NaOMe (1.03 g, 19.0mmol) for 4
days. Under this procedure, 5 was obtained in 78% yield
(676mg).
2.1.4. General Procedure for the Synthesis of 7a–15a and 7b–
15b. To a solution of the 3,5-disubstituted triazole (1 equiv)
in 40% NaOH aq solution (3–5mL) and toluene (7–10mL)
(Bu)4NBr (0.05 equiv) were 	rst added, and later the cor-
responding alkylating agent (1 equiv) was added. e reac-
tion mixture was stirred at 80–90∘C (bath temperature)
for the reaction time indicated. Aerwards, organic layer
was separated and the aqueous layer was extracted with
CH2Cl2 (3 × 25mL). e combined organic layers were
dried over anhydrous Na2SO4 and the solvent was removed
in vacuo. e residue was puri	ed by MPLC [cyclohex-
ane/EtOAc (9 : 1)], except for compound 13a, which was puri-
	ed by ash chromatography [CH2Cl2 → CH2Cl2/MeOH
(60 : 1)].
1-Benzyl-5-heptyl-3-phenyl-1H-1,2,4-triazole (7a) and 1-Ben-
zyl-3-heptyl-5-phenyl-1H-1,2,4-triazole (7b). Compounds 7a
and 7b were prepared from 3 (100mg, 0.4mmol),
benzyl bromide (52휇L, 0.4mmol), and (Bu)4NBr (6mg,
0.02mmol); reaction time: 1.5 h. Yield: 106mg of 7a (78%)
as a transparent oil, and 13mg of 7b (9%) as a transparent
oil. 7a: 1H-NMR (CDCl3) 훿: 8.08 (m, 2H, Ph); 7.40 (m, 3H,
Ph); 7.31 (m, 3H, Bn); 7.18 (m, 2H, Bn); 5.34 (s, 2H, CH2Ph);
2.69 (t, 2H, 퐽 = 7.8Hz, CH2CH2CH2CH2CH2CH2CH3);
1.64 (p, 2H, 퐽 = 7.5Hz, CH2CH2CH2CH2CH2CH2CH3);
1.22 (m, 8H, CH2CH2CH2CH2CH2CH2CH3); 0.85 (bt,
3H, 퐽 = 6.1Hz, CH3). 13C-NMR (CDCl3) 훿: 160.8 C3;
157.0 C5; 135.7 Cipso Bn; 131.2 Cipso Ph; 128.9 Cm Bn and
Cp Ph; 128.5 Cm Ph; 126.9 Co Bn; 126.3 Co Ph; 128.1 Cp
Bn; 52.1 (CH2Ph); 31.6 CH2CH2CH2CH2CH2CH2CH3;
29.2 CH2CH2CH2CH2CH2CH2CH3; 28.8 CH2CH2CH2
CH2CH2CH2CH3; 27.8 CH2CH2CH2CH2CH2CH2CH3; 26.2
CH2CH2CH2CH2CH2CH2CH3; 22.5 CH2CH2CH2CH2CH2
CH2CH3; 14.0 CH3. MS (ES+) m/z: 334 (100%) [M+H]+.
Anal (C22H27N3) % calculated (% found) C: 79.24 (79.35);
H: 8.16 (8.40); N: 12.60 (12.64). 7b: 1H-NMR (CDCl3)훿: 7.53 (m, 2H, Ph); 7.41 (m, 3H, Ph); 7.30 (m, 3H,
Bn); 7.14 (m, 2H, Bn); 5.35 (s, 2H, CH2Ph); 2.75 (t, 2H,퐽 = 7.7Hz, CH2CH2CH2CH2CH2CH2CH3); 1.78 (p, 2H,퐽 = 7.7Hz, CH2CH2CH2CH2CH2CH2CH3); 1.23 (m, 8H,
CH2CH2CH2CH2CH2CH2CH3); 0.85 (bt, 3H, 퐽 = 6.4Hz,
CH3). 13C-NMR (CDCl3) 훿: 164.1 C3; 155.3 C5; 136.1
Cipso Bn; 130.2 Cipso Ph; 128.9 Cm Bn; 128.8 and 128.7
Co and Cm Ph; 126.7 Co Bn; 127.9 Cp Bn and Cp Ph; 52.4
CH2Ph; 31.8 CH2CH2CH2CH2CH2CH2CH3; 29.3 CH2CH2
CH2CH2CH2CH2CH3; 29.0 CH2CH2CH2CH2CH2CH2
CH3; 28.5 CH2CH2CH2CH2CH2CH2CH3; 28.3 CH2CH2
CH2CH2CH2CH2CH3; 22.6 CH2CH2CH2CH2CH2CH2
CH3; 14.1 CH3. MS (ES+) m/z: 334 (100%) [M+H]+. Anal
(C22H27N3) % calculated (% found) C: 79.24 (79.10); H: 8.16
(7.95); N: 12.60 (12.42).
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1-(4-Chlorobenzyl)-5-heptyl-3-phenyl-1H-1,2,4-triazole (8a)
and 1-(4-Chlorobenzyl)-3-heptyl-5-phenyl-1H-1,2,4-triazole
(8b). Compounds 8a and 8b were prepared from 3 (73mg,
0.3mmol), 4-chlorobenzyl chloride (48mg, 0.3mmol), and
(Bu)4NBr (6mg, 0.02mmol); reaction time: 11 h. Yield:
96mg of 8a (87%) as a yellow solid and 10mg of 8b (9%) as
a transparent oil. 8a: 1H-NMR (CDCl3) 훿: 8.07 (m, 2H, Ho
Ph); 7.37 (m, 3H, Hm and Hp Ph); 7.29 (d, 2H, 퐽 = 8.4Hz,
Hm Bn); 7.11 (d, 2H, 퐽 = 8.4Hz, Ho Bn); 5.27 (s, 2H, CH2Ar);
2.67 (t, 2H, 퐽 = 7.7Hz, CH2CH2CH2CH2CH2CH2CH3);
1.69 (p, 2H, 퐽 = 7.7Hz, CH2CH2CH2CH2CH2CH2CH3);
1.24 (m, 8H, CH2CH2CH2CH2CH2CH2CH3); 0.85 (ta, 3H,퐽 = 6.9Hz, CH3). 13C-NMR (CDCl3) 훿: 161.0 C3; 156.9
C5; 134.2 Cipso Bn; 134.0 Cp Bn; 131.1 Cipso Ph; 129.0 and
128.3 Co Bn, Cm Bn and Cp Ph; 128.5 Cm Ph; 126.2 Co
Ph; 51.3 CH2Ar; 31.5 CH2CH2CH2CH2CH2CH2CH3; 29.2
CH2CH2CH2CH2CH2CH2CH3; 28.8 CH2CH2CH2CH2CH2
CH2CH3; 27.7CH2CH2CH2CH2CH2CH2CH3; 26.1CH2CH2
CH2CH2CH2CH2CH3; 22.5 CH2CH2CH2CH2CH2CH2
CH3; 14.0 CH3. MS (ES+) m/z: 368 (100%) [M+H]+. Anal
(C22H26ClN3) % calculated (% found) C: 71.82 (71.75); H:
7.12 (6.98); N: 11.42 (11.63). 8b: 1H-NMR (CDCl3) 훿: 7.50 (m,
2H, H Ph); 7.43 (m, 3H, Ph); 7.29 (d, 2H, 퐽 = 8.4Hz, Hm
Bn); 7.06 (d, 2H, 퐽 = 8.4Hz, Ho Bn); 5.30 (s, 2H, CH2Ar);
2.75 (t, 2H, 퐽 = 7.5Hz, CH2CH2CH2CH2CH2CH2CH3);
1.77 (p, 2H, 퐽 = 7.5Hz, CH2CH2CH2CH2CH2CH2CH3);
1.23 (m, 8H, CH2CH2CH2CH2CH2CH2CH3); 0.85 (ta, 3H,퐽 = 6.2Hz, CH3). 13C-NMR (CDCl3) 훿: 164.6 C3; 155.5
C5; 134.7 Cipso Bn; 133.8 Cp Bn; 130.1 Cp Ph; 129.0 Cm Bn;
128.8 Co Bn; 128.6 Cm Ph; 128.1 Co Ph; 128.0 Cipso Ph; 51.7
CH2Ar; 31.8 CH2CH2CH2CH2CH2CH2CH3; 29.4 CH2CH2
CH2CH2CH2CH2CH3; 29.0 CH2CH2CH2CH2CH2CH2
CH3; 28.5 CH2CH2CH2CH2CH2CH2CH3; 22.6 CH2CH2
CH2CH2CH2CH2CH3; 14.1 CH3. MS (ES+) m/z: 368 (100%)
[M+H]+. HPLC: Acetonitrile/H2O 95 : 5, 푡푅 = 28.5min (99%
purity).
1-(2,4-Dichlorobenzyl)-5-heptyl-3-phenyl-1H-1,2,4-triazole
(9a) and 1-(2,4-Dichloro-benzyl)-3-heptyl-5-phenyl-1H-1,2,4-
triazole (9b). Compounds 9a and 9b were prepared from
3 (100mg, 0.4mmol), 2,4-dichlorobenzyl chloride (57 휇L,
0.4mmol), and (Bu)4NBr (6mg, 0.02mmol); reaction time:
5 h. Yield: 123mg of 9a (74%) as a white solid and 12mg of
9b (7%) as a transparent oil. 9a: Mp = 70–73∘C. 1H-NMR
(CDCl3) 훿: 8.11 (m, 2H, Ho Ph); 7.42 (m, 4H, Hm耠 Bn, Hm
and Hp Ph); 7.19 (dd, 1H, J = 8.3Hz and 1.6Hz, Hm Ph); 6.85
(d, 1H, 퐽 = 8.3Hz, Ho Bn); 5.41 (s, 2H, CH2Ar); 2.73 (t, 2H,퐽 = 7.7Hz, CH2CH2CH2CH2CH2CH2CH3); 1.73 (p, 2H,퐽 = 7.7Hz, CH2CH2CH2CH2CH2CH2CH3); 1.27 (m, 8H,
CH2CH2CH2CH2CH2CH2CH3); 0.88 (bt, 3H, 퐽 = 6.4Hz,
CH3). 13C-NMR(CDCl3) 훿: 161.4C3; 157.4C5; 134.5CipsoBn;
132.8 Cp Bn; 132.2 Co耠 Bn; 131.0 Cipso Ph; 129.3 Co Bn; 129.2
Cm耠 Bn; 129.1 Cp Ph; 128.5 Cm Ph; 127.7 Cm Bn; 126.3 Co Ph;
48.6 CH2Ar; 31.5 CH2CH2CH2CH2CH2CH2CH3; 29.1 CH2
CH2CH2CH2CH2CH2CH3; 28.8 CH2CH2CH2CH2CH2CH2
CH3; 27.8 CH2CH2CH2CH2CH2CH2CH3; 26.0 CH2CH2
CH2CH2CH2CH2CH3; 22.5 CH2CH2CH2CH2CH2CH2
CH3; 14.0 CH3. MS (ES+) m/z: 402 (100%) [M+H]+. Anal
(C22H25Cl2N3) % calculated (% found) C: 65.67 (65.42);
H: 6.26 (6.50); N: 10.44 (10.35). 9b: 1H-NMR (CDCl3) 훿:
7.50–7.43 (m, 5H, Ph); 7.40 (d, 1H, 퐽 = 1.7Hz, Hm耠 Bn);
7.20 (dd, 1H, 퐽 = 8.6Hz and 1.7Hz, Hm Bn); 6.84 (d,
1H, 퐽 = 8.6Hz, Ho Bn); 5.39 (s, 2H, CH2Ar); 2.76 (t, 2H,퐽 = 7.7Hz, CH2CH2CH2CH2CH2CH2CH3); 1.79 (p, 2H,퐽 = 7.7Hz, CH2CH2CH2CH2CH2CH2CH3); 1.23 (m, 8H,
CH2CH2CH2CH2CH2CH2CH3); 0.85 (bt, 3H, 퐽 = 6.1Hz,
CH3). 13C-NMR (CDCl3) 훿: 165.2 C3; 156.2 C5; 134.6 Cipso
Bn; 133.0 Cp Bn; 132.9 Co耠 Bn; 130.5 Co Bn; 129.7 Cm耠 Bn;
129.2 Cm Ph; 129.0 Cp Ph; 128.6 Co Ph; 127.9 Cm Bn; 127.8
Cipso Ph; 50.1 CH2Ar; 32.0 CH2CH2CH2CH2CH2CH2CH3;
29.6 CH2CH2CH2CH2CH2CH2CH3; 29.2 CH2CH2CH2CH2
CH2CH2CH3; 28.7 CH2CH2CH2CH2CH2CH2CH3; 22.9
CH2CH2CH2CH2CH2CH2CH3; 14.3 CH3. MS (ES+) m/z:
402 (100%) [M+H]+. Anal (C22H25Cl2N3⋅C6H12) % calcu-
lated (% found) C: 69.12 (69.42); H: 7.67 (7.79); N: 8.64 (8.24).
1-Benzyl-3-(4-chlorophenyl)-5-heptyl-1H-1,2,4-triazole (10a)
and 1-Benzyl-5-(4-chlo-rophenyl)-3-heptyl-1H-1,2,4-triazole
(10b). Compounds 10a and 10b were prepared from 4
(80mg, 0.3mmol), benzyl bromide (34 휇L, 0.3mmol), and
(Bu)4NBr (6mg, 0.02mmol); reaction time: 20min. Yield:
94mg of 10a (89%) as a white solid and 9mg of 10b (8%) as a
yellow oil. 10a: Mp = 47–50∘C. 1H-NMR (CDCl3) 훿: 8.02 (d,
2H, 퐽 = 8.8Hz, Ho Ar); 7.36 (d, 2H, 퐽 = 8.8Hz, Hm Ar); 7.29
(m, 3H, Bn); 7.19 (m, 2H, Bn); 5.31 (s, 2H, CH2Ph); 2.67 (t, 2H,퐽 = 7.7Hz, CH2CH2CH2CH2CH2CH2CH3); 1.66 (p, 2H,퐽 = 7.7Hz, CH2CH2CH2CH2CH2CH2CH3); 1.22 (m, 8H,
CH2CH2CH2CH2CH2CH2CH3); 0.85 (bt, 3H, 퐽 = 6.9Hz,
CH3). 13C-NMR (CDCl3) 훿: 159.9 C3; 157.1 C5; 135.5 Cipso
Ar; 134.7 Cipso Bn; 129.8 Cp Ar; 128.9 Cm Ar; 128.6 Cm Bn;
128.1 Cp Bn; 127.6 Co Ar; 126.9 Co Bn; 52.1 (CH2Ph); 31.5
CH2CH2CH2CH2CH2CH2CH3; 29.2 CH2CH2CH2CH2CH2
CH2CH3, 28.8 CH2CH2CH2CH2CH2CH2CH3; 27.7 CH2
CH2CH2CH2CH2CH2CH3; 26.1 CH2CH2CH2CH2CH2CH2
CH3; 22.5 CH2CH2CH2CH2CH2CH2CH3; 14.0 CH3.
MS (ES+) m/z: 368 (100%) [M+H]+. Anal (C22H26ClN3)
% calculated (% found) C: 71.82 (72.02); H: 7.12 (6.89);
N: 11.42 (11.24). 10b: 1H-NMR (CDCl3) 훿: 7.47 (d, 2H,퐽 = 8.5Hz, Hm Ar); 7.38 (d, 2H, 퐽 = 8.5Hz, Ho Ar);
7.30 (m, 3H, Bn); 7.00 (m, 2H, Bn); 5.33 (s, 2H, CH2Ph);
2.75 (t, 2H, 퐽 = 7.6Hz, CH2CH2CH2CH2CH2CH2CH3);
1.78 (p, 2H, 퐽 = 7.6Hz, CH2CH2CH2CH2CH2CH2CH3);
1.25 (m, 8H, CH2CH2CH2CH2CH2CH2CH3); 0.85 (bt,
3H, 퐽 = 6.4Hz, CH3). 13C-NMR (CDCl3) 훿: 164.6
C3; 155.0 C5; 136.3 Cipso Ar; 136.2 Cipso Bn; 130.0 Cm
Ar; 129.4 Cp Ar; 129.1 Co Ar; 129.0 Cm Bn; 128.0 Cp
Bn; 52.6 (CH2Ph); 31.8 CH2CH2CH2CH2CH2CH2CH3;
29.4 CH2CH2CH2CH2CH2CH2CH3; 29.0 CH2CH2CH2
CH2CH2CH2CH3; 28.5 CH2CH2CH2CH2CH2CH2CH3;
22.6 CH2CH2CH2CH2CH2CH2CH3; 14.0 CH3. MS (ES+)
m/z: 368 (100%) [M+H]+.
1-(4-Chlorobenzyl)-3-(4-chlorophenyl)-5-heptyl-1H-1,2,4-tria-
zole (11a) and 1-(4-Chlo-robenzyl)-5-(4-chlorophenyl)-3-
heptyl-1H-1,2,4-triazole (11b). Compounds 11a and 11b were
prepared from4 (100mg, 0.4mmol), 4-chlorobenzyl chloride
(64mg, 0.4mmol), and (Bu)4NBr (6mg, 0.02mmol);
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reaction time: 6 h. Yield: 132mg of 11a (91%) as a white solid
and 2mg of 11b (1%) as a transparent oil. 11a: Mp = 58–60∘C.1H-NMR (CDCl3) 훿: 8.00 (d, 2H, 퐽 = 8.8Hz, Ho Ar); 7.35 (d,
2H, 퐽 = 8.8Hz, HmAr); 7.28 (d, 2H, 퐽 = 8.4Hz, HmCH2Ar);
7.10 (d, 2H, 퐽 = 8.4Hz, Ho CH2Ar); 5.26 (s, 2H, CH2Ar);
2.66 (t, 2H, 퐽 = 7.7Hz, CH2CH2CH2CH2CH2CH2CH3);
1.66 (p, 2H, 퐽 = 7.7Hz, CH2CH2CH2CH2CH2CH2CH3);
1.23 (m, 8H, CH2CH2CH2CH2CH2CH2CH3); 0.84 (bt, 3H,퐽 = 6.3Hz, CH3). 13C-NMR (CDCl3) 훿: 160.1 C3; 157.1 C5;
134.8 Cipso Ar; 134.1 Cipso CH2Ar; 134.0 Cp CH2Ar; 129.6
CpAr; 129.0 CmAr; 128.6 Cm CH2Ar; 128.3 Co CH2Ar; 127.5
Co Ar; 51.3 (CH2Ar); 31.5 CH2CH2CH2CH2CH2CH2CH3;
29.2 CH2CH2CH2CH2CH2CH2CH3; 28.8 CH2CH2CH2
CH2CH2CH2CH3; 27.7 CH2CH2CH2CH2CH2CH2CH3; 26.1
CH2CH2CH2CH2CH2CH2CH3; 22.5 CH2CH2CH2CH2CH2
CH2CH3; 14.0 CH3. MS (ES+) m/z: 402 (100%) [M+H]+.
Anal (C22H25Cl2N3) % calculated (% found) C: 65.67 (65.72);
H: 6.26 (6.12); N: 10.44 (10.40). 11b: 1H-NMR (CDCl3) 훿:
7.45 (d, 2H, 퐽 = 9.0Hz, Ho Ar); 7.39 (d, 2H, 퐽 = 9.0Hz,
Hm Ar); 7.30 (d, 2H, 퐽 = 8.3Hz, Hm CH2Ar); 7.05 (d,
2H, 퐽 = 8.3Hz, Ho CH2Ar); 5.29 (s, 2H, CH2Ar); 2.70
(t, 2H, 퐽 = 7.8Hz, CH2CH2CH2CH2CH2CH2CH3); 1.75
(p, 2H, 퐽 = 7.8Hz, CH2CH2CH2CH2CH2CH2CH3); 1.23
(m, 8H, CH2CH2CH2CH2CH2CH2CH3); 0.82 (bt, 3H,퐽 = 6.2Hz, CH3). 13C-NMR (CDCl3) 훿: 164.7 C3; 154.4
C5; 136.4 Cipso Ar; 134.4 Cipso CH2Ar; 134.0 Cp CH2Ar;
129.9 Cm and Cp Ar; 129.2 Co Ar and Cm CH2Ar; 128.0 Co
CH2Ar; 51.8 CH2Ar; 31.8 CH2CH2CH2CH2CH2CH2CH3;
29.7 CH2CH2CH2CH2CH2CH2CH3; 29.3 CH2CH2CH2
CH2CH2CH2CH3; 29.0 CH2CH2CH2CH2CH2CH2CH3;
28.4CH2CH2CH2CH2CH2CH2CH3; 22.6 CH2CH2CH2CH2
CH2CH2CH3; 14.1 CH3. MS (ES+)m/z: 402 (100%) [M+H]+.
HPLC: Acetonitrile/H2O 95 : 5, 푡푅 = 25.5min (81% purity).
3-(4-Chlorophenyl)-1-(2,4-dichlorobenzyl)-5-heptyl-1H-1,2,4-
triazole (12a) and 5-(4-Chlorophenyl)-1-(2,4-dichlorobenzyl)-
3-heptyl-1H-1,2,4-triazole (12b). Compounds 12a and 12b
were prepared from 4 (90mg, 0.3mmol), 2,4-dichlorobenzyl
chloride (45 휇L, 0.3mmol), and (Bu)4NBr (6mg, 0.02mmol);
reaction time: 6 h. Yield: 122mg of 12a (86%) as a white solid
and 8mg of 12b (6%) as a transparent oil. 12a: Mp = 97–99∘C.1H-NMR (CDCl3) 훿: 8.00 (d, 2H, 퐽 = 8.6Hz, Ho Ar); 7.41
(d, 1H, 퐽 = 2.0Hz, Hm耠 CH2Ar); 7.37 (d, 2H, 퐽 = 8.6Hz,
Hm Ar); 7.18 (dd, 1H, 퐽 = 8.4Hz and 2.0Hz, Hm CH2Ar);
6.84 (d, 1H, 퐽 = 8.4Hz, Ho CH2Ar); 5.37 (s, 2H, CH2Ar);
2.70 (t, 2H, 퐽 = 7.6Hz, CH2CH2CH2CH2CH2CH2CH3);
1.69 (p, 2H, 퐽 = 7.6Hz, CH2CH2CH2CH2CH2CH2CH3);
1.22 (m, 8H, CH2CH2CH2CH2CH2CH2CH3); 0.85 (bt, 3H,퐽 = 7.1Hz, CH3). 13C-NMR (CDCl3) 훿: 160.5 C3; 157.6
C5; 135.0 Cipso Ar; 134.6 Cipso CH2Ar; 132.9 Cp CH2Ar;
132.0 Co耠 CH2Ar; 129.5 Cp Ar; 129.4 Co CH2Ar; 129.3 Cm耠
CH2Ar; 128.7 Cm Ar; 127.7 Cm CH2Ar; 127.6 Co Ar; 48.7
CH2Ar; 31.5 CH2CH2CH2CH2CH2CH2CH3; 29.1 CH2CH2
CH2CH2CH2CH2CH3; 28.8 CH2CH2CH2CH2CH2CH2
CH3; 27.7 CH2CH2CH2CH2CH2CH2CH3; 26.0 CH2CH2
CH2CH2CH2CH2CH3; 22.5 CH2CH2CH2CH2CH2CH2
CH3; 14.0 CH3. MS (ES+) m/z: 436 (100%) [M+H]+. Anal
(C22H24Cl3N3) % calculated (% found) C: 60.49 (60.42);
H: 5.54 (5.74); N: 9.62 (9.42). 12b: 1H-NMR (CDCl3) 훿:
7.41 (bs, 5H, Ho Ar, Hm Ar and Hm耠 CH2Ar); 7.21 (dd, 1H,퐽 = 8.3Hz and 2.0Hz, Hm CH2Ar); 6.84 (d, 1H, 퐽 = 8.3Hz,
Ho CH2Ar); 5.37 (s, 2H, CH2Ar); 2.75 (t, 2H, 퐽 = 7.7Hz,
CH2CH2CH2CH2CH2CH2CH3); 1.77 (p, 2H, 퐽 = 7.7Hz,
CH2CH2CH2CH2CH2CH2CH3); 1,23 (m, 8H, CH2CH2
CH2CH2CH2CH2CH3); 0.85 (bt, 3H, 퐽 = 6.1Hz, CH3).13C-NMR (CDCl3) 훿: 165.1 C3; 154.9 C5; 136.6 Cipso Ar;
134.7 Cipso CH2Ar; 132.8 Cp CH2Ar; 132.5 Co耠 CH2Ar; 129.7
Cm and Cp Ar; 129.6 Co CH2Ar; 129.3 Co Ar; 129.0 Cm耠
CH2Ar; 127.8 Cm CH2Ar; 49.9 CH2Ar; 31.8 CH2CH2CH2
CH2CH2CH2CH3; 29.7 CH2CH2CH2CH2CH2CH2CH3;
29.3 CH2CH2CH2CH2CH2CH2CH3; 29.0 CH2CH2CH2CH2
CH2CH2CH3; 28.4 CH2CH2CH2CH2CH2CH2CH3; 22.6
CH2CH2CH2CH2CH2CH2CH3; 14.0 CH3. MS (ES+) m/z:
436 (99%) [M+H]+. HPLC: Acetonitrile/H2O 90 : 10, 푡푅 =66.2min (99% purity).
4-(1-Benzyl-5-heptyl-1H-1,2,4-triazol-3-yl)pyridine (13a).
Compound 13a was prepared from 5 (150mg, 0.6mmol),
benzyl chloride (73휇L, 0.6mmol), and (Bu)4NBr (6mg,
0.02mmol); reaction time: 2.5 h. Yield: 166mg of 13a
(81%) as an orange oil. 1H-NMR (CDCl3) 훿: 8.63 (d, 2H,퐽 = 6.0Hz, Hm pyr); 7.93 (d, 2H, 퐽 = 6.0Hz, Ho pyr);
7.31 (m, 3H, Ph); 7.16 (m, 2H, Ph); 5.33 (s, 2H, CH2Ar);
2.68 (t, 2H, 퐽 = 7.8Hz, CH2CH2CH2CH2CH2CH2CH3);
1.65 (p, 2H, 퐽 = 7.0Hz, CH2CH2CH2CH2CH2CH2CH3);
1.21 (m, 8H, CH2CH2CH2CH2CH2CH2CH3); 0.83 (bt,
3H, 퐽 = 7.1Hz, CH3). 13C-NMR (CDCl3) 훿: 158.7 C3;
157.5 C5; 150.1 Cm pyr; 138.5 Cipso pyr; 135.2 Cipso Ph;
128.9 Cm Ph; 128.2 Cp Ph; 127.0 Co Ph; 120.4 Co pyr; 52.3
CH2Ph; 31.5 CH2CH2CH2CH2CH2CH2CH3; 29.1 CH2CH2
CH2CH2CH2CH2CH3; 28.8 CH2CH2CH2CH2CH2CH2
CH3; 27.6 CH2CH2CH2CH2CH2CH2CH3; 26.1 CH2CH2
CH2CH2CH2CH2CH3; 22.5 CH2CH2CH2CH2CH2CH2
CH3; 14.0 CH3. MS (ES+) m/z: 335 (100%) [M+H]+. Anal
(C21H26N4) % calculated (% found) C: 75.41 (75.71); H: 7.84
(7.79); N: 16.75 (16.54).
4-[1-(4-Chlorobenzyl)-5-heptyl-1H-1,2,4-triazol-3-yl]pyridine
(14a) and 4-[1-(4-Chlo-robenzyl)-3-heptyl-1H-1,2,4-triazol-5-
yl]pyridine (14b). Compounds 14a and 14b were prepared
from 5 (180mg, 0.7mmol), 4-chlorobenzyl chloride (119mg,
0.7mmol), and (Bu)4NBr (12mg, 0.04mmol); reaction time:
6 h. Yield: 150mg of 14a (51%) as a brown solid and 10mg
of 14b (4%) as a brown oil. 14a: Mp = 77–80∘C. 1H-NMR
(CDCl3) 훿: 8.61 (d, 2H, 퐽 = 6.0Hz, Hm pyr); 7.90 (d, 2H,퐽 = 6.0Hz, Ho pyr); 7.27 (d, 2H, 퐽 = 8.6Hz, Hm Ar);
7.09 (d, 2H, 퐽 = 8.6Hz, Ho Ar); 5.27 (s, 2H, CH2Ar); 2.66
(t, 2H, 퐽 = 7.8Hz, CH2CH2CH2CH2CH2CH2CH3); 1.65
(p, 2H, 퐽 = 7.8Hz, CH2CH2CH2CH2CH2CH2CH3); 1.20
(m, 8H, CH2CH2CH2CH2CH2CH2CH3); 0.82 (bt, 3H,퐽 = 6.6Hz, CH3). 13C-NMR (CDCl3) 훿: 158.9 C3; 157.5
C5; 150.2 Cm pyr; 138.4 Cipso pyr; 134.2 Cipso Ar; 133.7 Cp
Ar; 129.1 Cm Ar; 128.4 Co Ar; 120.4 Co pyr; 51.8 CH2Ar;
31.5 CH2CH2CH2CH2CH2CH2CH3; 29.1 CH2CH2CH2
CH2CH2CH2CH3; 28.8 CH2CH2CH2CH2CH2CH2CH3;
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26.0CH2CH2CH2CH2CH2CH2CH3; 22.5 CH2CH2CH2CH2
CH2CH2CH3; 14.0 CH3. MS (ES+)m/z: 369 (100%) [M+H]+.
Anal (C21H25ClN4) % calculated (% found) C: 68.37 (68.55);
H: 6.83 (6.90); N: 15.19 (15.21). 14b: 1H-NMR (CDCl3) 훿:
8.65 (d, 2H, 퐽 = 6.2Hz, Hm pyr); 7.44 (d, 2H, 퐽 = 6.2Hz, Ho
pyr); 7.31 (d, 2H, 퐽 = 8.5Hz, Hm Ar); 7.06 (d, 2H, 퐽 = 8.5Hz,
Ho pyr); 5.35 (s, 2H, CH2Ar); 2.76 (t, 2H, 퐽 = 7.6Hz,
CH2CH2CH2CH2CH2CH2CH3); 1.74 (p, 2H, 퐽 = 7.6Hz,
CH2CH2CH2CH2CH2CH2CH3); 1.27 (m, 8H, CH2CH2CH2
CH2CH2CH2CH3); 0.85 (m, 3H,CH3). 13C-NMR (CDCl3) 훿:
165.1 C3; 152.8 C5; 150.5 Cm pyr; 135.4 Cipso pyr; 134.2 Cipso
Ar; 134.0 Cp Ar; 129.3 Cm Ar; 128.0 Co Ar; 122.5 Co pyr; 52.1
CH2Ar; 31.7 CH2CH2CH2CH2CH2CH2CH3; 29.3 CH2CH2
CH2CH2CH2CH2CH3; 29.2 CH2CH2CH2CH2CH2CH2
CH3; 28.4 and 29.0 CH2CH2CH2CH2CH2CH2CH3; 22.6
CH2CH2CH2CH2CH2CH2CH3; 14.1 CH3. MS (ES+) m/z:
369 (100%) [M+H]+.
4-[1-(2,4-Dichlorobenzyl)-5-heptyl-1H-1,2,4-triazol-3-yl]pyri-
dine (15a) and 4-[1-(2,4-Dichlorobenzyl)-3-heptyl-1H-1,2,4-
triazol-5-yl]pyridine (15b). Compounds 15a and 15b were
prepared from 5 (200mg, 0.8mmol), 2,4-dichlorobenzyl
chloride (114 휇L, 0.8mmol), and (Bu)4NBr (12mg,
0.04mmol.); reaction time: 2 h. Yield: 118mg of 15a (36%)
as a white solid and 7mg of 15b (2%) as a yellow oil. 15a: Mp
= 104-105∘C. 1H-NMR (CDCl3) 훿: 8.65 (d, 2H, 퐽 = 6.1Hz,
Hm pyr); 7.93 (d, 2H, 퐽 = 6.1Hz, Ho pyr); 7.42 (d, 1H,퐽 = 2.2Hz, Hm耠 Ar); 7.19 (dd, 1H, 퐽 = 8.4Hz and 2.2Hz, Hm
Ar); 6.58 (d, 1H, 퐽 = 8.4Hz, Ho Ar); 5.39 (s, 2H, CH2Ar);
2.72 (t, 2H, 퐽 = 7.7Hz, CH2CH2CH2CH2CH2CH2CH3);
1.70 (p, 2H, 퐽 = 7.7Hz, CH2CH2CH2CH2CH2CH2CH3);
1.23 (m, 8H, CH2CH2CH2CH2CH2CH2CH3); 0.84 (bt, 3H,퐽 = 6.5Hz, CH3). 13C-NMR (CDCl3) 훿: 159.3 C3; 158.1 C5;
150.3 Cm pyr; 138.3 Cipso pyr; 134.8 Cipso Ar; 133.0 Cp Ar;
131.7 Co耠 Ar; 129.5 Co and Cm耠 Ar; 127.8 Cm Ar; 120.4 Co
pyr; 48.9 (CH2Ar); 31.6 CH2CH2CH2CH2CH2CH2CH3; 29.1
CH2CH2CH2CH2CH2CH2CH3; 28.8 CH2CH2CH2CH2CH2
CH2CH3; 27.7 CH2CH2CH2CH2CH2CH2CH3; 26.0 CH2
CH2CH2CH2CH2CH2CH3; 22.5 CH2CH2CH2CH2CH2
CH2CH3; 14.0 CH3. MS (ES+) m/z: 403 (100%) [M+H]+.
Anal (C21H24Cl2N4) % calculated (% found) C: 62.53
(62.28); H: 6.00 (6.30); N: 13.89 (14.04). 15b: 1H-NMR
(CDCl3) 훿: 8.70 (d, 2H, 퐽 = 6.1Hz, Hm pyr); 7.43 (d, 1H,퐽 = 2.2Hz, Hm耠 Ar); 7.41 (d, 2H, 퐽 = 6.1Hz, Ho pyr);
7.19 (dd, 1H, 퐽 = 8.1Hz and 2.2Hz, Hm Ar); 6.85 (d, 1H,퐽 = 8.1Hz, Ho Ar); 5.44 (s, 2H, CH2Ar); 2.77 (t, 2H,퐽 = 7.6Hz, CH2CH2CH2CH2CH2CH2CH3); 1.73 (p, 2H,퐽 = 7.6Hz, CH2CH2CH2CH2CH2CH2CH3); 1.25 (m, 8H,
CH2CH2CH2CH2CH2CH2CH3); 0.85 (ta, 3H, 퐽 = 6.7Hz,
CH3). 13C-NMR (CDCl3) 훿: 165.5 C3; 152.8 C5; 150.6 Cm
pyr; 138.3 Cipso pyr; 135.1 Cipso Ar; 132.8 Cp Ar; 131.9 (Co耠
Ar); 129.7 Co Ar; 128.8 Cm耠 Ar; 127.8 Cm Ar; 122.3 Co
pyr; 50.1 CH2Ar; 31.6 CH2CH2CH2CH2CH2CH2CH3; 29.3
CH2CH2CH2CH2CH2CH2CH3; 29.0 CH2CH2CH2CH2CH2
CH2CH3; 28.3 CH2CH2CH2CH2CH2CH2CH3; 22.6 CH2
CH2CH2CH2CH2CH2CH3; 14.1 CH3. MS (ES+) m/z: 403
(100%) [M+H]+. HPLC: Acetonitrile/H2O 90 : 10, 푡푅 =30.3min (90% purity).
2.1.5. General Procedure for the Synthesis of 16–18. To a
solution of the corresponding triazole (1 equiv) in dryCH2Cl2
(4–10mL), excess of MeI was added. e reaction mixture
was stirred at room temperature for the time indicated.
Aerwards, solvent was removed in vacuo and the residue
was puri	ed by chromatography or recrystallization from
Et2O/CH2Cl2.
4-(1-Benzyl-5-heptyl-1H-1,2,4-triazol-3-yl)-1-methylpyridini-
um Iodide (16). Compound 16was prepared from 13a (15mg,
0.05mmol) and MeI (4 휇L, 0.07mmol); reaction time: 16 h.
Puri	cation: ash chromatography [CH2Cl2/MeOH (99 : 1)→CH2Cl2/MeOH (9 : 1)]. Yield: 14mg of 16 (66%) as a yellow
gummy solid. 1H-NMR (CDCl3) 훿: 9.18 (d, 2H, 퐽 = 6.7Hz,
Hm pyr); 8.54 (d, 2H, 퐽 = 6.7Hz, Ho pyr); 7.35 (m, 3H, Ph);
7.19 (m, 2H, Ph); 5.36 (s, 2H, CH2Ar); 4.68 (s, 3H, NMe);
2.71 (t, 2H, 퐽 = 7.6Hz, CH2CH2CH2CH2CH2CH2CH3);
1.67 (p, 2H, 퐽 = 7.6Hz, CH2CH2CH2CH2CH2CH2CH3);
1.23 (m, 8H, CH2CH2CH2CH2CH2CH2CH3); 0.85 (bt,
3H, 퐽 = 7.0Hz, CH3). 13C-NMR (CDCl3) 훿: 159.0 C3;
155.3 C5; 146.7 Cipso pyr; 145.6 Cm pyr; 134.3 Cipso Ph;
129.1 Cm Ph; 128.6 Cp Ph; 127.3 Co Ph; 123.7 Co pyr; 53.0
CH2Ar; 49.1 NMe; 31.5 CH2CH2CH2CH2CH2CH2CH3;
29.0 CH2CH2CH2CH2CH2CH2CH3; 28.8 CH2CH2CH2
CH2CH2CH2CH3; 27.2 CH2CH2CH2CH2CH2CH2CH3; 26.1
CH2CH2CH2CH2CH2CH2CH3; 22.5 CH2CH2CH2CH2CH2
CH2CH3; 14.0 CH3. MS (ES+) m/z: 349 (100%), [M]+. Anal
(C22H29IN4) % calculated (% found) C: 55.47 (55.42); H: 6.14
(6.30); N: 11.76 (11.57).
4-[1-(4-Chlorobenzyl)-5-heptyl-1H-1,2,4-triazol-3-yl]-1-meth-
ylpyridinium Iodide (17). Compound 17 was prepared
from 14a (70mg, 0.2mmol) and MeI (140 휇L 2.3mmol);
reaction time: 8 days. Puri	cation: ash chromatography
[CH2Cl2/MeOH (95 : 5)]. Yield: 87mg of 17 (90%) as a
yellow gummy solid. 1H-NMR (CDCl3) 훿: 9.21 (d, 2H,퐽 = 6.8Hz, Hm pyr); 8.54 (d, 2H, 퐽 = 6.8Hz, Ho pyr); 7.33
(d, 2H, 퐽 = 8.5Hz, Hm Ar); 7.15 (d, 2H, 퐽 = 8.5Hz, Ho
Ar); 5.33 (s, 2H, CH2Ar); 4.68 (s, 3H, NMe); 2.71 (t, 2H,퐽 = 7.5Hz, CH2CH2CH2CH2CH2CH2CH3); 1.69 (p, 2H,퐽 = 7.5Hz, CH2CH2CH2CH2CH2CH2CH3); 1.23 (m, 8H,
CH2CH2CH2CH2CH2CH2CH3); 0.85 (bt, 3H, 퐽 = 6.5Hz,
CH3). 13C-NMR (CDCl3) 훿: 158.9 C3; 155.4 C5; 146.3 Cipso
pyr; 145.7 Cm pyr; 134.4 Cipso Ar; 132.7 Cp Ar; 129.1 Cm
Ar; 128.7 Co Ar; 123.5 Co pyr; 52.1 CH2Ar; 48.9 NMe; 31.4
CH2CH2CH2CH2CH2CH2CH3; 28.9 CH2CH2CH2CH2CH2
CH2CH3; 28.6 CH2CH2CH2CH2CH2CH2CH3; 27.0 CH2
CH2CH2CH2CH2CH2CH3; 25.9 CH2CH2CH2CH2CH2CH2
CH3; 22.4 CH2CH2CH2CH2CH2CH2CH3; 13.9 CH3. MS
(ES+) m/z: 383 (100%) [M]+. Anal (C22H28ClIN4) % calcu-
lated (% found) C: 51.73 (51.58); H: 5.52 (5.41); N: 10.97
(10.72).
4-[1-(2,4-Dichlorobenzyl)-5-heptyl-1H-1,2,4-triazol-3-yl]-1-
methylpyridinium Iodide (18). Compound 18 was prepared
from 15a (50mg, 0.1mmol) and MeI (277 휇L 4.45mmol);
reaction time: 8 days. Puri	cation: recrystallization from
Et2O/CH2Cl2. Yield: 43mg of 18 (64%) as a yellow solid. Mp
= 136–138∘C. 1H-NMR (CDCl3) 훿: 9.22 (d, 2H, 퐽 = 6.7Hz,
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( )6
·HCl
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hydrochloride
Scheme 2: Reagents: (i) NaOMe, dry EtOH, N2 atm; (ii) NH4Cl,
N2 atm; (iii) octanoic hydrazide, NaOMe, dry EtOH, Δ; and (iv)
NaOMe, dry EtOH, Δ.
Hm pyr); 8.53 (d, 2H, 퐽 = 6.7Hz, Ho pyr); 7.44 (d, 1H,퐽 = 1.9Hz, Hm耠 Ar); 7.25 (dd, 1H, 퐽 = 8.4Hz and 1.9Hz,
Hm Ar); 7.00 (d, 1H, 퐽 = 8.4Hz, Ho Ar); 5.42 (s, 2H,
CH2Ar); 4.69 (s, 3H, NMe); 2.76 (t, 2H, 퐽 = 7.6Hz,
CH2CH2CH2CH2CH2CH2CH3); 1.72 (p, 2H, 퐽 = 7.6Hz,
CH2CH2CH2CH2CH2CH2CH3); 1.26 (m, 8H, CH2CH2
CH2CH2CH2CH2CH3); 0.86 (bt, 3H, 퐽 = 7.3Hz, CH3).13C-NMR (CDCl3) 훿: 159.4 C3; 155.8 C5; 146.5 Cipso pyr;
145.7 Cm pyr; 135.4 CipsoAr; 133.4 CpAr; 130.6 Co耠 Ar; 130.3
Co Ar; 129.7 Cm耠 Ar; 128,0 (Cm BnAr); 123,7 (Co CAr); 49,5
(CH2Ar); 49,2 (NMe); 31.5 CH2CH2CH2CH2CH2CH2CH3;
29.0 CH2CH2CH2CH2CH2CH2CH3; 28.8 CH2CH2CH2CH2
CH2CH2CH3; 27.3 CH2CH2CH2CH2CH2CH2CH3; 25.9
CH2CH2CH2CH2CH2CH2CH3; 22.5 CH2CH2CH2CH2CH2
CH2CH3; 14.0 CH3. MS (ES+) m/z: 417 (100%) [M]+. Anal
(C22H27Cl2IN4) % calculated (% found) C: 48.46 (48.71); H:
4.99 (5.20); N: 10.27 (10.06).
2.2. Pharmacology
Radioligand Binding Assays. CB1R binding assays in rat
cerebellarmembraneswere performedusing [3H]-SR141716A
and [3H]-WIN552122 (NEN-Dupont, Boston, MA, 40–
60Ci/mmol) as radioligands, using the previously described
methods [14].퐾푖 were calculated from the equation of Yung-
Chi and Pruso [15], using 	xed 퐾푑 values for either [3H]-
WIN552122 (8 nM) or [3H]-SR141716A (4 nM) obtained from
independent experimental assays.
3. Results and Discussion
3.1. Chemistry. 5-Aryl-3-heptyl-1H-1,2,4-triazoles were 	rst
synthesized, and then they were alkylated with dierent
N
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+
Scheme 3: Reagents: (i) benzyl bromide for 7a-7b, 10a-10b, and
13a; 4-chlorobenzyl chloride for 8a-8b, 11a-11b, and 14a-14b; and
2,4-dichlorobenzyl chloride for 9a-9b, 12a-12b, and 15a-15b; 40%
NaOH aq, Bu4NBr, and toluene, 80∘C.
benzyl halide reagents. Preparation of disubstituted tria-
zoles 3–5 is depicted in Scheme 2. In the 	rst step, 4-
chlorobenzonitrile and 4-cyanopyridine reacted successively
with sodium methoxide and ammonium chloride under
inert conditions to aord amidinium hydrochlorides 1 and
2, respectively. Triazoles 3–5 were obtained from 1, 2 and
the commercially available benzamidine hydrochloride in
moderate yields by reuxing them with octanoic hydrazide
under basic conditions. Cyclization of 4-amidinopyridinium
hydrochloride (2) was incomplete and the addition interme-
diate6was allowed to be isolated. Acylamidrazone6was then
cyclized to 5 under the same basic conditions (Scheme 2).
e second step took place with the alkylation of triazoles
3–5 under phase transfer catalysis conditions, using an
aqueous sodium hydroxide solution as base and toluene
as organic solvent [16]. ese conditions were chosen aer
unsuccessful attempts of alkylation in an organic solvent
(tetrahydrofuran) with mild (sodium bicarbonate) or strong
(sodium hydride) bases. As depicted in Scheme 3, reaction
of 3–5 with dierent benzyl halides in the presence of tetra-
butylammonium bromide yielded two products by alkylation
on N2 (7a–15a) or N1 (7b–15b) of the triazole. Alkylation
on N4 of the triazole was not detected, since its formation is
hindered by steric reasons. Both alkylated isomers were easily
isolated by chromatography, being the N2-benzyl derivatives
obtained in greater proportion (≈10 : 1). e only N1 isomer
that could not be isolated and characterized was 13b; however
it was detected by HPLC during the synthesis of 13a. Higher
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Scheme 4: Reagents: (i) MeI (excess), CH2Cl2, rt.
ratio of N2 isomers was obtained by alkylation of 5 with 4-
chlorobenzyl and 2,4-dichlorobenzyl chlorides that led to a
mixture of N2/N1 isomers in proportion of 13 : 1 and 18 : 1,
respectively. ese results support the fact that alkylation
of 1,2,4-triazoles with benzyl halides is governed by steric
reasons.
Since compounds 7–15 are very lipophilic, pyridinium
salts (16–18; Scheme 4) of some of the triazolylpyridines
previously obtained were synthesized in order to test if
they possessed improved aqueous solubility compared to the
parent compounds. Increasing the aqueous solubility was
important to perform the radioligand binding assays of the
series of benzyl triazoles. erefore, compounds 13a–15a
readily reacted with an excess of methyl iodide (1.5 equiv for
13a, 11 equiv for 14a, and 44 equiv for 15a). Achievement of
the triazolyl-1-methyl pyridinium salts needed long reaction
times (16 h for 16 and 8 days for 17 and 18), but the products
were obtained in good yields.
Qualitative solubility tests of compounds 16–18 did not
show any improvement in their solubility in water; therefore
they were not assessed by pharmacological assays.
3.2. Radioligand Binding Assays. Competitive radioligand
binding assays have been used to evaluate the anity of
selected synthetized triazoles to CB1R in rat cerebellar mem-
branes. ey have been performed with [3H]-SR141716A and
[3H]-WIN552122 as labelled ligands. e results of these
preliminary assays are reported in Table 1.
Table 1: Anity of compounds 7a-8a and 10a–12a and the reference
cannabinoids SR141716 and LH21 for CB1R determined using rat
cerebellar membranes and [3H]-SR141716 or [3H]-WIN552122 as
radioligand. 퐾푖 values were obtained from three independent
experiments carried out in triplicate and are expressed as mean ±
standard error.
Compound
퐾푖 (nM) CB1R
versus
[3H]-SR141617
퐾푖 (nM) CB1R
versus
[3H]-WIN552122
SR141716 퐾푑 = 0.59 4
LH21 855.6 ± 296 748 ± 193
7a 436 ± 120 477 ± 94
8a 589 ± 136 561 ± 125
10a 389.5 ± 180 2437 ± 888
11a 562 ± 183 720 ± 165
12a 13.9 ± 2.4 323 ± 60.5
Compound 12a showed high CB1R anity versus [3H]-
SR141617 (퐾푖 = 13.9 nM) and moderate anity versus [3H]-
WIN552122 (퐾푖 = 323 nM). ese binding data indicate that
12a displaced better SR141617, an inverse agonist of CB1R,
than WIN552122, an agonist of CB1R. Since both SR141716
and WIN552122 have been reported in the literature to bind
to CB1R in the same binding pocket [17], the results obtained
here suggest that 12a binds to the inactive state of CB1R, as
the inverse agonists do (e.g., SR141716), and not to the active
state of the receptor, as the agonists do (e.g.,WIN552122) [18].
e other tested compounds 7a, 8a, 10a, and 11a showed
moderate CB1R anity with anity constant values in the
low micromolar range.
In what refers to the binding to CB2R, none of the
compounds showed signi	cant anity using [3H]-CP55940
as radioligand in membranes puri	ed from cells transfected
with human CB2R (data not shown).
4. Conclusions
In our ongoing program searching for novel cannabinoid lig-
ands, we reported a CB1R antagonist [5-(4-chlorophenyl)-1-
(2,4-dichlorophenyl)-3-hexyl-1H-1,2,4-triazole, LH21], which
showed an interesting in vitro and in vivo pharmacological
pro	le and was able to reduce food intake and body weight
in obese animals with major peripheral components. In the
present study, we have explored structural modi	cations on
this 1,2,4-triazole scaold. A series of new 3(5)-alkyl-5(3)-
aryl-1-benzyl-1H-1,2,4-triazoles were synthesized and com-
petitive binding assays of selected compounds were carried
out. One of these triazoles (12a) showed high anity for
CB1R.
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